APP
PCVX icon

Alpha Paradigm Partners’s Vaxcyte PCVX Stock Holding History

Alpha Paradigm Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$368K Buy
+7,665
New +$301K 0.15% 212

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Alpha Paradigm Partners's PCVX Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Vaxcyte (PCVX) in Q4 2022: 7,665 shares worth $368K. The stake represents 0.15% of the portfolio and ranks #212 among its holdings.

198 funds tracked by Wall St. Rank hold PCVX as of Q4 2022.

  • Alpha Paradigm Partners held 7,665 shares of Vaxcyte worth $368K as of Q4 2022.
  • Vaxcyte was a new Alpha Paradigm Partners position in Q4 2022.
  • Vaxcyte made up 0.15% of Alpha Paradigm Partners's portfolio in Q4 2022, its #212 holding.
  • 198 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.